Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
ACAD's Cash-to-Debt is ranked higher than
98% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. ACAD: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ACAD' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.56  Med: 212.01 Max: 98090
Current: No Debt
5.56
98090
Equity-to-Asset 0.91
ACAD's Equity-to-Asset is ranked higher than
88% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ACAD: 0.91 )
Ranked among companies with meaningful Equity-to-Asset only.
ACAD' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.13  Med: 0.8 Max: 0.98
Current: 0.91
-2.13
0.98
Interest Coverage No Debt
ACAD's Interest Coverage is ranked higher than
98% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ACAD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ACAD' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 62.70
Beneish M-Score: 351.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -488.75
ACAD's Operating Margin % is ranked lower than
77% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. ACAD: -488.75 )
Ranked among companies with meaningful Operating Margin % only.
ACAD' s Operating Margin % Range Over the Past 10 Years
Min: -269855.74  Med: -1339.85 Max: 35.82
Current: -488.75
-269855.74
35.82
Net Margin % -485.14
ACAD's Net Margin % is ranked lower than
78% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. ACAD: -485.14 )
Ranked among companies with meaningful Net Margin % only.
ACAD' s Net Margin % Range Over the Past 10 Years
Min: -269578.69  Med: -1333.65 Max: 35.93
Current: -485.14
-269578.69
35.93
ROE % -64.26
ACAD's ROE % is ranked lower than
65% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. ACAD: -64.26 )
Ranked among companies with meaningful ROE % only.
ACAD' s ROE % Range Over the Past 10 Years
Min: -138.68  Med: -63.43 Max: 72.43
Current: -64.26
-138.68
72.43
ROA % -59.32
ACAD's ROA % is ranked lower than
72% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. ACAD: -59.32 )
Ranked among companies with meaningful ROA % only.
ACAD' s ROA % Range Over the Past 10 Years
Min: -78.95  Med: -55.21 Max: 34.38
Current: -59.32
-78.95
34.38
ROC (Joel Greenblatt) % -9679.01
ACAD's ROC (Joel Greenblatt) % is ranked lower than
87% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. ACAD: -9679.01 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACAD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -21643.52  Med: -9123.53 Max: 2028.76
Current: -9679.01
-21643.52
2028.76
3-Year Revenue Growth Rate 126.00
ACAD's 3-Year Revenue Growth Rate is ranked higher than
96% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ACAD: 126.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ACAD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -77.6  Med: -34.55 Max: 126
Current: 126
-77.6
126
3-Year EBITDA Growth Rate 73.70
ACAD's 3-Year EBITDA Growth Rate is ranked higher than
94% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. ACAD: 73.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ACAD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -53  Med: -11 Max: 73.7
Current: 73.7
-53
73.7
3-Year EPS without NRI Growth Rate 74.60
ACAD's 3-Year EPS without NRI Growth Rate is ranked higher than
95% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. ACAD: 74.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACAD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -36.6  Med: -5.35 Max: 74.6
Current: 74.6
-36.6
74.6
» ACAD's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ACAD Guru Trades in Q3 2016

George Soros 17,645 sh (New)
Jana Partners 149,252 sh (New)
Steven Cohen 2,071,500 sh (+72.67%)
Steven Cohen 120,300 sh (unchged)
» More
Q4 2016

ACAD Guru Trades in Q4 2016

Joel Greenblatt 25,682 sh (New)
Jana Partners 301,243 sh (+101.84%)
George Soros Sold Out
Steven Cohen 1,225,000 sh (-40.86%)
» More
Q1 2017

ACAD Guru Trades in Q1 2017

George Soros 8,900 sh (New)
Paul Singer 777,382 sh (New)
Steven Cohen 1,931,200 sh (+57.65%)
Jana Partners 421,140 sh (+39.80%)
Joel Greenblatt Sold Out
» More
Q2 2017

ACAD Guru Trades in Q2 2017

Paul Tudor Jones 16,847 sh (New)
Paul Singer 1,256,795 sh (+61.67%)
George Soros Sold Out
Jana Partners Sold Out
Steven Cohen 1,406,022 sh (-27.19%)
» More
» Details

Insider Trades

Latest Guru Trades with ACAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2017-06-30 Sold Out 0.01%$25.45 - $34.71 $ 37.6726%0
George Soros 2017-03-31 New Buy0.01%$28.77 - $39.85 $ 37.677%8,900
Joel Greenblatt 2017-03-31 Sold Out 0.01%$28.77 - $39.85 $ 37.677%0
Joel Greenblatt 2016-12-31 New Buy0.01%$20.87 - $30.71 $ 37.6742%25,682
George Soros 2016-12-31 Sold Out 0.02%$20.87 - $30.71 $ 37.6742%0
George Soros 2016-09-30 New Buy0.02%$30.87 - $37.44 $ 37.6711%17,645
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:TECH, NAS:JUNO, NAS:UTHR, NAS:NBIX, NAS:PBYI, NAS:CLVS, NAS:FGEN, NAS:NKTR, NAS:BLUE, NAS:AGIO, NAS:PTLA, NAS:ONCE, NAS:BIVV, NAS:AVXS, NAS:SRPT, NAS:LGND, NAS:IONS, NAS:TSRO, NAS:LOXO, NAS:BPMC » details
Traded in other countries:DR6.Germany,
Headquarter Location:USA
ACADIA Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. It aims to discover small molecule drugs to address Parkinson's, Alzheimer's and schizophrenia.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Top Ranked Articles about ACADIA Pharmaceuticals Inc

InvestorsObserver releases covered-call reports for ACADIA Pharmaceuticals, Aerie Pharmaceuticals, Best Buy Inc., Marathon Oil Corporation and Walgreens Boots Alliance
Insiders Roundup: Facebook, Twitter, Kellogg Largest insider trades of the week
The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$5,000,000+,” the duration to “February 2017” and All Insider Sales to “$5,000,000+.” Read more...

Ratios

vs
industry
vs
history
PB Ratio 11.11
ACAD's PB Ratio is ranked lower than
75% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. ACAD: 11.11 )
Ranked among companies with meaningful PB Ratio only.
ACAD' s PB Ratio Range Over the Past 10 Years
Min: 0.48  Med: 5.87 Max: 16.67
Current: 11.11
0.48
16.67
PS Ratio 72.37
ACAD's PS Ratio is ranked lower than
85% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. ACAD: 72.37 )
Ranked among companies with meaningful PS Ratio only.
ACAD' s PS Ratio Range Over the Past 10 Years
Min: 0.66  Med: 53.95 Max: 39600
Current: 72.37
0.66
39600
EV-to-EBIT -13.61
ACAD's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. ACAD: -13.61 )
Ranked among companies with meaningful EV-to-EBIT only.
ACAD' s EV-to-EBIT Range Over the Past 10 Years
Min: -73.5  Med: -6.45 Max: 6.3
Current: -13.61
-73.5
6.3
EV-to-EBITDA -13.72
ACAD's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. ACAD: -13.72 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACAD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -73.7  Med: -6.55 Max: 6.1
Current: -13.72
-73.7
6.1
EV-to-Revenue 66.51
ACAD's EV-to-Revenue is ranked lower than
80% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. ACAD: 66.51 )
Ranked among companies with meaningful EV-to-Revenue only.
ACAD' s EV-to-Revenue Range Over the Past 10 Years
Min: -17.6  Med: 43 Max: 25951.9
Current: 66.51
-17.6
25951.9
Current Ratio 10.85
ACAD's Current Ratio is ranked higher than
82% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ACAD: 10.85 )
Ranked among companies with meaningful Current Ratio only.
ACAD' s Current Ratio Range Over the Past 10 Years
Min: 2.27  Med: 6.45 Max: 46.41
Current: 10.85
2.27
46.41
Quick Ratio 10.70
ACAD's Quick Ratio is ranked higher than
82% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. ACAD: 10.70 )
Ranked among companies with meaningful Quick Ratio only.
ACAD' s Quick Ratio Range Over the Past 10 Years
Min: 2.27  Med: 6.45 Max: 46.41
Current: 10.7
2.27
46.41
Days Inventory 220.23
ACAD's Days Inventory is ranked lower than
72% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. ACAD: 220.23 )
Ranked among companies with meaningful Days Inventory only.
ACAD' s Days Inventory Range Over the Past 10 Years
Min: 220.23  Med: 247.78 Max: 247.78
Current: 220.23
220.23
247.78
Days Sales Outstanding 67.18
ACAD's Days Sales Outstanding is ranked lower than
63% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. ACAD: 67.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACAD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.18  Med: 1585.63 Max: 9801.15
Current: 67.18
67.18
9801.15
Days Payable 186.13
ACAD's Days Payable is ranked higher than
78% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. ACAD: 186.13 )
Ranked among companies with meaningful Days Payable only.
ACAD' s Days Payable Range Over the Past 10 Years
Min: 186.13  Med: 464.35 Max: 464.35
Current: 186.13
186.13
464.35

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.00
ACAD's 3-Year Average Share Buyback Ratio is ranked higher than
56% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. ACAD: -10.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACAD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -153  Med: -23.9 Max: -2
Current: -10
-153
-2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 12.27
ACAD's Price-to-Net-Cash is ranked lower than
52% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. ACAD: 12.27 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ACAD' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.69  Med: 6.42 Max: 19.49
Current: 12.27
0.69
19.49
Price-to-Net-Current-Asset-Value 11.45
ACAD's Price-to-Net-Current-Asset-Value is ranked lower than
52% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. ACAD: 11.45 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ACAD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.66  Med: 5.98 Max: 18.47
Current: 11.45
0.66
18.47
Price-to-Tangible-Book 11.28
ACAD's Price-to-Tangible-Book is ranked lower than
66% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ACAD: 11.28 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ACAD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.63  Med: 5.66 Max: 18.19
Current: 11.28
0.63
18.19
Price-to-Median-PS-Value 1.34
ACAD's Price-to-Median-PS-Value is ranked lower than
82% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ACAD: 1.34 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACAD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 0.55 Max: 649.2
Current: 1.34
0.02
649.2
Earnings Yield (Greenblatt) % -7.36
ACAD's Earnings Yield (Greenblatt) % is ranked lower than
57% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. ACAD: -7.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACAD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -4328.3  Med: -7.7 Max: 51153
Current: -7.36
-4328.3
51153

More Statistics

Revenue (TTM) (Mil) $62.99
EPS (TTM) $ -2.53
Beta4.45
Short Percentage of Float22.31%
52-Week Range $20.68 - 40.83
Shares Outstanding (Mil)122.40

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 113 234 487 841
EPS ($) -2.56 -1.51 0.16 1.65
EPS without NRI ($) -2.56 -1.51 0.16 1.65
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}